KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Non-Current Debt (2022 - 2025)

Adaptive Biotechnologies' Non-Current Debt history spans 4 years, with the latest figure at $126.6 million for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 4.42% year-over-year to $126.6 million; the TTM value through Dec 2025 reached $126.6 million, down 4.42%, while the annual FY2025 figure was $126.6 million, 4.42% down from the prior year.
  • Non-Current Debt for Q4 2025 was $126.6 million at Adaptive Biotechnologies, down from $129.4 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $132.7 million in Q3 2024 and bottomed at $125.4 million in Q4 2022.
  • The 4-year median for Non-Current Debt is $130.7 million (2023), against an average of $130.0 million.
  • The largest annual shift saw Non-Current Debt grew 4.71% in 2024 before it decreased 4.42% in 2025.
  • A 4-year view of Non-Current Debt shows it stood at $125.4 million in 2022, then grew by 4.23% to $130.7 million in 2023, then grew by 1.34% to $132.4 million in 2024, then dropped by 4.42% to $126.6 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Non-Current Debt are $126.6 million (Q4 2025), $129.4 million (Q3 2025), and $130.5 million (Q2 2025).